Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share
DNA.WS
DNA.WS was delisted on the 3rd of September, 2024.
58 hedge funds and large institutions have $40.7M invested in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share in 2021 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 14 increasing their positions, 5 reducing their positions, and 27 closing their positions.
180% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 5
0% less capital invested
Capital invested by funds: $40.8M → $40.7M (-$87.1K)
18% less funds holding
Funds holding: 71 → 58 (-13)
44% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 27
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
+$4.4M |
| 2 |
LP
LMR Partners
London,
United Kingdom
|
+$3.74M |
| 3 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
+$3.13M |
| 4 |
ICM
Ionic Capital Management
New York
|
+$2.45M |
| 5 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$2.45M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCP
Diameter Capital Partners
New York
|
-$5.58M |
| 2 |
ICM
Indaba Capital Management
San Francisco,
California
|
-$3.67M |
| 3 |
GL
Governors Lane
New York
|
-$1.36M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$809K |
| 5 |
Skandinaviska Enskilda Banken (SEB)
Stockholm,
Sweden
|
-$630K |
DNA.WS Hedge Fund Activity: Q4 2021 in Review
58 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) for Q4 2021, worth a combined $40.7M — down 0.21% from $40.8M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of DNA.WS and 15 opened new positions — a net loss of 12 holders — while 5 trimmed existing stakes and 14 added.
The largest buyer was Weiss Asset Management, opening a new position worth an estimated $4.4M. The largest seller was Diameter Capital Partners, exiting entirely with an estimated $5.58M sold.
- 58 institutional investors held Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) as of Q4 2021, down from 71 in Q3 2021.
- Funds reported $40.7M of Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share stock for Q4 2021, down 0.21% quarter-over-quarter.
- 15 funds opened new Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share positions in Q4 2021 and 27 closed out, a net change of -12 holders.
- The largest Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share buyer in Q4 2021 was Weiss Asset Management, an estimated $4.4M added.
- The largest Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share seller in Q4 2021 was Diameter Capital Partners, an estimated $5.58M sold.
Based on aggregated 13F filings for Q4 2021.